RBC Capital Reiterates Outperform on IDEAYA Biosciences, Maintains $61 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on IDEAYA Biosciences (NASDAQ:IDYA) and maintained a price target of $61.
August 07, 2024 | 4:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on IDEAYA Biosciences and maintained a price target of $61.
The reiteration of an Outperform rating and a maintained price target of $61 by RBC Capital is a positive signal for investors, likely boosting short-term confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100